Stock STRO SUTRO BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Sutro Biopharma, Inc.

Equities

STRO

US8693671021

Biotechnology & Medical Research

Delayed Nasdaq
Other stock markets
 01:00:00 2024-07-03 pm EDT 		5-day change 1st Jan Change
2.88 USD -2.70% Intraday chart for Sutro Biopharma, Inc. -1.87% -32.87%
Jun. 03 Vgxi Inc. Announces Strategic Partnership with Sutro Biopharma Inc. to Support Growing Clinical Pipeline CI
May. 13 Sutro Biopharma Q1 Loss Widens, Revenue Rises MT

Business Summary

Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Company’s advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed against folate receptor-alpha (FolRa), for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. It also has two preclinical product candidates, STRO-003 and STRO-004. These product candidates are single homogeneous ADCs directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), and tissue factor (TF), each of which is being developed for the treatment of solid tumors.

Number of employees: 300

Sales per Business

USD in Million2022Weight2023Weight Delta
Biopharmaceutical Products
100.0 %
68 100.0 % 154 100.0 % +126.84%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
68 100.0 % 154 100.0 % +126.84%

Managers

Managers TitleAgeSince
William Newell CEO
 Chief Executive Officer 66 09-01-13
Jane Chung PSD
 President 53 21-08-08
Edward Albini DFI
 Director of Finance/CFO 66 13-01-30
Steve Michel CTO
 Chief Tech/Sci/R&D Officer - -
Craig Berman CTO
 Chief Tech/Sci/R&D Officer - 20-05-20
Hans-Peter Gerber CTO
 Chief Tech/Sci/R&D Officer 61 23-09-17
Henry Heinsohn CTO
 Chief Tech/Sci/R&D Officer - -
Anne Borgman CTO
 Chief Tech/Sci/R&D Officer 56 23-02-27
Linda Fitzpatrick IRO
 Public Communications Contact 67 07-12-31
Werner Rubas PRN
 Corporate Officer/Principal - 21-09-15

Members of the board

Members of the board TitleAgeSince
Connie Matsui CHM
 Chairman 70 19-06-23
James Panek BRD
 Director/Board Member 71 20-01-06
Daniel Petree BRD
 Director/Board Member 68 -
John Freund BRD
 Director/Board Member 70 14-01-31
Joseph Lobacki BRD
 Director/Board Member 65 17-01-31
William Newell CEO
 Chief Executive Officer 66 09-01-13
Michael Dybbs BRD
 Director/Board Member 49 18-07-24
Heidi Hunter BRD
 Director/Board Member 65 21-11-18
Jon Wigginton BRD
 Director/Board Member 62 20-11-29

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 81,794,334 81,041,853 ( 99.08 %) 0 99.08 %

Shareholders

NameEquities%Valuation
Point72 Asset Management LP
7.253 %
5,932,908 7.253 % 25 M $
Suvretta Capital Management LLC
7.064 %
5,778,188 7.064 % 24 M $
BlackRock Advisors LLC
6.590 %
5,390,196 6.590 % 23 M $
Millennium Management LLC
5.790 %
4,735,963 5.790 % 20 M $
MPM BioImpact, Inc
5.008 %
4,096,619 5.008 % 17 M $
Vanguard Fiduciary Trust Co.
3.696 %
3,022,790 3.696 % 13 M $
Kynam Capital Management LP
2.447 %
2,001,727 2.447 % 8 M $
Adage Capital Partners GP LLC
2.445 %
2,000,000 2.445 % 8 M $
Baillie Gifford & Co.
2.258 %
1,846,906 2.258 % 8 M $
Parkman Healthcare Partners LLC
2.188 %
1,790,051 2.188 % 8 M $

Company contact information

Sutro Biopharma, Inc.

111 Oyster Point Boulevard

94080, South San Francisco

+650 881 6500

http://www.sutrobio.com
address Sutro Biopharma, Inc.(STRO)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for Sutro Biopharma, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
2.88 USD
Average target price
12.3 USD
Spread / Average Target
+327.08%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
SUTRO BIOPHARMA, INC. Stock Sutro Biopharma, Inc.
-32.87% 236M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+15.58% 121B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+16.60% 110B
ARGENX SE Stock argenx SE
+17.82% 25.93B
BIONTECH SE Stock BioNTech SE
-24.33% 19.27B
GENMAB A/S Stock Genmab A/S
-19.58% 16.01B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.95% 15.66B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-48.32% 14.89B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+58.78% 14.47B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.91% 13.91B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. STRO Stock
  4. Company Sutro Biopharma, Inc.